Our Value Proposal

Biomill was founded with the mission of dramatically improving patient access to medicines by producing them at significantly lower costs.

Our approach relies on innovative technologies that differ fundamentally from conventional CHO and E. coli based production. Specifically, we use Genetically Modified Bovines (GMB) as bioreactors to enable large-scale drug manufacturing at a fraction of the traditional cost.